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The effect of oral corticosteroids on bronchodilator 
responses in COPD 
Z. CORDEN AND P. J. REES 
UMDS Guy’s and St Thomas’ Hospital, London, U.K. 
There have been suggestions that corticosteroid treatment might improve bronchodilator responses in chronic 
obstructive pulmonary disease (COPD). We have studied bronchodilator responses to salbutamol and to oxitropium 
bromide in 20 patients with stable moderate to severe COPD. Dose responses to the two bronchodilators were tested 
before and after 3 week courses of placebo and 30 mg prednisolone. Thirteen patients were taking inhaled 
corticosteroids. There were no significant changes in numbers of responses or maximum bronchodilator effects from 
either bronchodilator, although there was a trend towards higher maximum levels after 3 weeks of prednisolone. 
Spirometry measured at home each morning before and after oxitropium bromide showed no difference between 
prednisolone and placebo periods. This study provides no evidence for a significant effect on bronchodilator 
responses to P-agonists or anticholinergic agents from 3 weeks of oral prednisolone in moderately severe COPD. 
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Introduction 
Oral corticosteroids are used widely in the treatment of 
chronic airflow obstruction. They have an established place 
in the treatment of acute exacerbations of asthma and in 
chronic severe asthma (1). In patients with stable chronic 
obstructive pulmonary disease (COPD) 2-3 week courses of 
steroids produce a clinically significant increase in forced 
expiratory volume in 1 s (FEV,) and forced vital capacity 
(FVC) in a minority of patients (2). Corticosteroids are 
often used in acute exacerbations of COPD (3,4). 
It has been suggested that oral corticosteroids might 
improve bronchodilator responses in airflow obstruction. 
In vitro p-receptor numbers are increased by corticosteroid 
treatment (5,6). They have been shown to increase the 
effects of b-adrenergic agonists in animal models and in 
human tissue in vitro (7,8). Treatment with corticosteroids 
can prevent or reverse decline in p-receptor density and the 
development of tolerance (9-l 1). 
A study in ten patients with COPD found a trend 
towards an increase in the bronchodilator response to 
ipratropium bromide after an 8 day course of oral corticos- 
teroids (12). Inhaled steroids for 3 months failed to change 
bronchodilator responses in smokers with mild airflow 
obstruction (13). We have explored this area further with a 
longer course of oral prednisolone in a larger group of 
patients with more severe COPD. The laboratory measure- 
ments of bronchodilator responses were complemented by 
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daily home spirometry measurements of responses to an 
anticholinergic agent. 
Methods 
Twenty subjects with COPD entered the study. Two 
patients dropped out during the first phase and 18 com- 
pleted the cross-over study. The study was approved by the 
local Research Ethics Committee. 
All patients were aged over 40 years with FEV, less than 
70% predicted and FEV,/FVC ratio less than 60%. All were 
smokers or ex-smokers and had a clinical diagnosis of 
COPD. Exclusion criteria were diabetes mellitus, left-heart 
failure, active peptic ulceration, clinical diagnosis of asthma 
or positive skin tests for common allergens. Patients who 
had a previous documented response to oral steroids or 
who had been on oral steroids in the past 3 months were 
excluded. 
All patients were receiving treatment with inhaled 
P-adrenergic agonists and some were taking inhaled anti- 
cholinergic drugs. These were continued as needed through 
the study except that inhaled bronchodilators were stopped 
for at least 8 h and oral bronchodilators and long-acting 
inhaled bronchodilators for at least 24 h before measuring 
bronchodilator responses. Thirteen of the 18 patients were 
taking inhaled corticosteroids, either beclomethasone 
dipropionate or budesonide. The median dose of inhaled 
steroid was 8OOpg daily (range 0-2OOOpg daily). These 
were continued throughout the study. 
Bronchodilator responses to salbutamol and oxitropium 
bromide were carried out on two consecutive days at the 
same time of day. Over the next 3 weeks subjects received 
prednisolone 30 mg daily orally or matching placebo. 
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Bronchodilator responses were repeated in the same order 
and at the same time over 2 days at the end of this 3 weeks. 
Then subjects crossed over to receive 3 weeks of the second 
oral medication followed by a repeat of their bronchodila- 
tor responses. The order of treatment and of dose-response 
curves were randomized. Patients were blind to the bron- 
chodilator medication. Patients and technicians were blind 
to the order of prednisolone and placebo. 
Compliance was assessed by tablet counting. Mean com- 
pliance was 96% (range 78-102%). Bronchodilators were 
given by supervised inhalation and the final dose by nebu- 
lizer. Doses of salbutamol were 100, 100, 200 and 5OOOpg. 
Doses of oxitropium bromide were 100, 100, 200 and 
1000 /Lug. 
Measurements of FEV,, and FVC were made on a 
dry bellows spirometer (Vitalograph). The best of three 
reproducible traces was used in the analysis. 
At home over the 6 weeks of the study each subject took 
their usual inhaled medication. In addition they were asked 
to take 200,ug oxitropium bromide each morning and to 
measure their FEV, and FVC on a portable turbine spirom- 
eter (Micromedical) before and 45 min after. The best FEV, 
and FVC from these three recordings were used. The mean 
oxitropium responses over the last 7 days of prednisolone 
and placebo treatment were compared by paired t test. 
Bronchodilator responses were analysed as absolute 
change from baseline value and as absolute level of FEV, to 
allow for baseline shifts from steroid therapy. Results after 
prednisolone and placebo were compared by paired t tests 
for salbutamol and oxitropium bromide. 
Responders were defined as those who achieved an FEV, 
response of at least 15% and 200 ml change from baseline 
or a vital capacity response of 15% and 350 ml. The 
numbers of responders were compared for the different 
periods. 
Results 
The mean age (range) of the patients was 69.9 years (56-81 
years); 16 of the 18 patients were men. Mean baseline FEV, 
was 0.86 1. 
There was a tendency for baseline spirometry values to 
increase after prednisolone (Figs 1 and 2). The only signifi- 
cant change was an increase in FVC after prednisolone 
compared with initial values (salbutamol day, 0.33 195% CI 
0.06-0.60 1, P=O.O2; oxitropium day, 0.26 1 95% CI - 0.03 
to +0.55 1, P=O.O7). Only one patient had an FEV, 
increase of 200 ml and 15% baseline with prednisolone. 
Overall there were ‘responses’ to salbutamol or oxitro- 
pium bromide on 63% of the days using the criteria of 
>15% and 0.20 1 for FEV,, ~0.35 1 and 15% for FVC. 
There were no differences in number of responders between 
salbutamol and oxitropium or between placebo and pred- 
nisolone days (Table 1). There were no carry-over effects 
to bronchodilator responses in the placebo period from 
prednisolone taken in the first period. 
When the changes in FEV, and FVC after prednisolone 
and placebo were examined, there were no significant 
differences. 
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FIG. 1. Absolute values of FEV, during dose-response 
curves to (a) salbutamol and (b) oxitropium bromide at 
the start of the study and after 3 weeks of prednisolone 
and placebo in 18 patients with COPD. +, initial; 
0, placebo; 0, prednisolone. 
Mean absolute levels of FEV, and FVC in response to 
salbutamol and oxitropium bromide are shown in Figs 1 
and 2. Absolute levels of FEV, and FVC during 
the dose-response curves showed no significant 
differences between placebo and prednisolone periods. The 
maximal levels reached after prednisolone and placebo 
are not significantly different although in three of the 
four measurements the highest values occurred on pred- 
nisolone. At the maximum doses of oxitropium bromide 
differences between prednisolone and placebo periods 
were 0.00 1 for FEV, (95% CI - 0.07 to +0.08 1) and 0.13 1 
for FVC (95% CI - 0.10 to +0.35 1). With salbutamol 
equivalent differences were 0.04 1 for FEV, (95% CI 
- 0.05 to +0.13 1) and 0.18 1 for FVC (95% CI - 0.07 to 
+0.43 1). 
Sixteen of the 18 subjects produced adequate home 
recordings of spirometry throughout the 6 weeks of the 
study. There were no significant differences between the 
mean absolute FEV, or FVC responses to oxitropium 
bromide during the last week of placebo and prednisolone 
treatment. The FEV, increase after oxitropium was 0.12 1 
on prednisolone and 0.141 on placebo (t=0.62, P=O.51; 
95% CI of difference - 0.14 to +O.lO 1). The FVC increase 
with oxitropium was 0.24 1 on prednisolone and 0.28 1 on 
placebo (t=0.17, P=O.26; 95% CI of difference -0.20 to 
+0.12 1). 
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FIG. 2. Absolute values of FVC during dose-response 
curves to (a) salbutamol and (b) oxitropium bromide at 
the start of the study and after 3 weeks of prednisolone 
and placebo in 18 patients with COPD. +, initial; 
0, placebo; 0, prednisolone. 
The results in the five patients who were not taking 
inhaled corticosteroids were no different from those of the 
whole group. 
Discussion 
In this group of 18 patients with moderate to severe COPD 
there was a trend to an increase in baseline levels of FEV, 
and FVC after 3 weeks of oral prednisolone, as expected. 
Most studies show that around lO-20% of such patients will 
achieve a significant improvement in a formal trial of 
steroids (2) but in this study those shown previously to 
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respond to steroids were excluded. The only significant 
change in baseline levels with 3 weeks prednisolone was an 
increase in baseline levels of FVC. Only one individual 
showed a significant change in FEV,. 
There were no significant differences in bronchodilator 
responses expressed as changes from baseline during the 
prednisolone and placebo periods. The most significant 
change in bronchodilator response for patients with mod- 
erately severe COPD might be considered to be an increase 
in the maximal levels reached with bronchodilators on top 
of any corticosteroid response. For the absolute levels of 
FEV, and FVC there was a trend towards higher values on 
prednisolone than placebo but none of these changes was 
statistically significant. The 95”/0 confidence intervals for 
differences between prednisolone and placebo did not cover 
a possible clinically significant effect on FEV,. The upper 
limit of the 95% confidence intervals for FVC change did 
not exclude an effect up to 0.43 1. We cannot rule out 
the possibility of an FVC change of marginal clinical 
significance in a larger study. 
All the patients in this study had been taking inhaled 
bronchodilators. Anticholinergic agents do not lose their 
effect with repeated use (14) but small changes may occur 
with P-agonists (15). Reversal of any reduced effectiveness 
might result in an increased bronchodilator response after 
corticosteroids but such changes were not seen in this study. 
Thirteen patients were taking inhaled steroids. A previous 
study has shown that there is no effect on bronchodilator 
responses from 3 months of inhaled steroids at a dose of 
600 pg budesonide twice daily (13). This is greater than the 
median dose of inhaled steroids in the 13 users in this study. 
Our results show that additional use of oral steroids does 
not have a significant effect on bronchodilator responses. 
Responders to bronchodilators are sometimes taken to 
be those who show a change outside the 95% confidence 
intervals of the test. For FEV, this requires a change 
approaching 200 ml and for FVC around 350 ml (16.17). 
Overall 63% of challenges produced a response on this basis 
and numbers of responders to P-agonist and anticholinergic 
drugs were similar. With these criteria the number of 
responders was not significantly changed by 3 weeks of 
treatment with prednisolone. 
Bronchodilator responses are known to vary between 
assessments (l&19). We used home measurements to look 
at the consistency of responses in the usual clinical situ- 
ation. Sixteen patients were able to produce reproducible 
home recordings of FEV, and FVC with their responses to 
TABLE 1. Numbers of ‘responders’ to oxitropium bromide and salbutamol after placebo and 
prednisolone periods 
Oxitropium 
Salbutamol 
FEV, increase FVC increase 
>200 ml, n >350 ml,n 
Prednisolone Placebo Prednisolone Placebo 
9 9 13 13 
12 10 13 11 
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inhaled oxitropium bromide. The last week of the 3 weeks 
of recordings was used to avoid any carry-over effect from 
the previous treatment period. These results confirmed the 
laboratory measurements showing no difference between 
prednisolone and placebo weeks. The size of the changes 
was a little smaller on home recordings than in the respir- 
atory function laboratory. Probably this reflects a different 
degree of effort for home and technician-supervised record- 
ings. However, it was encouraging that the majority of this 
selected group of patients were able to produce adequate 
recordings at home with simple portable equipment. 
Spirometry is likely to be more useful than the simpler peak 
expiratory flow in the monitoring of patients with COPD, 
in contrast to asthma. 
The findings in this study provide no evidence for a 
clinically important increase in bronchodilator responses to 
either P-adrenergic or anticholinergic agents with a 3 week 
course of 30 mg oral prednisolone in moderate to severe 
COPD. 
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